Market capitalization | $490.83m |
Enterprise Value | $321.32m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 2.88 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-103.20m |
Free Cash Flow (TTM) Free Cash Flow | $-89.11m |
Cash position | $196.33m |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
8 Analysts have issued a Savara, Inc. forecast:
8 Analysts have issued a Savara, Inc. forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.28 -0.28 |
56%
56%
|
|
EBITDA | -103 -103 |
72%
72%
|
EBIT (Operating Income) EBIT | -103 -103 |
72%
72%
|
Net Profit | -96 -96 |
75%
75%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Savara, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. Its products include AeroVanc, Molgradex, GM-CSF, and Aironite. The company was founded on April 27, 2017 and is headquartered in Austin, TX.
Head office | United States |
CEO | Matthew Pauls |
Employees | 59 |
Founded | 1995 |
Website | www.savarapharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.